獸用疫苗市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會與預測，按疫苗類型、技術、地區、競爭細分

2022年，全球獸用疫苗市場估值達到84.4億美元，預計在預測期內將呈現令人印象深刻的成長，到2028年實現7.28%的年複合成長率（CAGR）。該市場是重要組成部分在更廣泛的獸醫保健行業中，包括旨在預防和管理動物（包括伴侶動物（寵物）和牲畜）疾病的疫苗的研究、生產和分銷。獸用疫苗在維護動物健康、確保糧食安全和減輕可在動物和人類之間傳播的人畜共通傳染病的傳播方面發揮關鍵作用。

主要市場促進因素

市場概況
預測期	2024-2028
2022 年市場規模	84.4億美元
2028 年市場規模	128.8億美元
2023-2028 年年複合成長率	7.28%
成長最快的細分市場	減毒活疫苗
最大的市場	北美洲

動物疾病發生率上升

全球獸用疫苗市場受到動物傳染病發生率上升的顯著影響。這些疾病可能影響多種物種，包括牲畜（牛、家禽、豬）和伴侶動物（狗、貓）。此類疾病的實例包括口蹄疫、禽流感、牛呼吸道疾病和犬小病毒。動物疾病可能造成嚴重的經濟後果。疫情爆發可能導致牲畜生產力下降、死亡率上升和貿易限制。對於農民和牲畜生產者來說，這會帶來巨大的經濟損失。為了減輕這些影響，開發和施用疫苗來預防這些疾病的發生和傳播。 「同一個健康」的概念強調人類、動物和環境健康的相互連結。預防動物疾病不僅對動物的福祉至關重要，對公共衛生也至關重要。可以從動物傳染給人類的疾病（人畜共通傳染病）凸顯了獸用疫苗在保護動物和人類方面的重要性。

動物福利意識不斷增強

由於人們對動物福祉的認知和關注不斷增強，公眾對動物福利的態度發生了顯著轉變。寵物主人更願意投資寵物的醫療保健，包括疫苗接種，以確保它們的健康和長壽。在畜牧業中，人們越來越認知到健康和精心照顧的動物可以提高生產力和食品安全。消費者對道德和永續來源的動物產品的要求越來越高，這激勵畜牧生產者優先考慮動物健康和福利。監管機構和動物福利組織推出了鼓勵人道對待動物的準則和認證計畫。這些指南通常包括透過疫苗接種來預防疾病的建議。

疫苗開發的技術進步

生物技術和基因組學的進步徹底改變了疫苗的開發。研究人員現在可以更精確地識別抗原並設計針對特定病原體的疫苗。這導致了安全性得到改善的亞單位疫苗和重組疫苗的開發。科技創新也改善了疫苗輸送方法。傳統的注射疫苗正在以口服疫苗和鼻內疫苗等替代品作為補充，這些疫苗可以更容易施用，並且可以減輕動物的壓力。現代疫苗開發技術能夠生產高效且安全的疫苗。這給獸醫、寵物主人和牲畜生產者註入了信心，鼓勵更多的疫苗採用。

政府措施和法規：

世界上許多國家的政府都針對動物的特定疾病實施了強制性疫苗接種計劃。例如，一些地區需要對牛隻進行布魯氏菌病疫苗接種，以防止疾病傳播。牲畜疫苗接種通常與食品安全和國際貿易法規有關。政府可能要求接種某些疫苗，以確保人類消費的動物性產品的安全性並促進國際貿易。政府和公共衛生機構經常資助與動物疫苗相關的研究和開發工作。這種財政支持可以促進針對各種動物物種的新疫苗和改進疫苗的發現和開發。

主要市場挑戰

監管障礙和核准流程

複雜的監管環境：獸用疫苗的開發和行銷涉及複雜的監管環境。不同國家和地區有自己的疫苗核准監管機構和要求。對於疫苗製造商來說，遵守這些法規可能既耗時又昂貴。

嚴格的安全性和有效性標準：監管機構對獸用疫苗實施嚴格的安全性和有效性標準，以確保動物的福祉並防止對人類健康的潛在風險。滿足這些標準通常需要進行廣泛的臨床前和臨床測試，這可能既昂貴又耗時。

疫苗註冊延遲：獸用疫苗註冊和批准的延遲可能會顯著減緩市場成長。製造商必須投資研究、開發和臨床試驗，批准過程中的任何延誤都會阻礙他們及時將疫苗推向市場的能力。

市場分散化與競爭挑戰

全球獸用疫苗市場分散，生產商眾多，包括跨國製藥公司和規模較小的專業公司。這種碎片化可能導致激烈的競爭和定價壓力。農民和寵物主人等客戶在獸用疫苗方面通常對價格敏感。這可能使疫苗製造商保持獲利能力面臨挑戰，特別是在與低成本替代品競爭時。由於監管要求、分銷管道和當地偏好的差異，向新興市場擴張可能會很困難。製造商必須調整策略以適應每個資源密集型市場。

新興疾病和抗原變異

新的、不可預測的動物疾病的出現可能為獸用疫苗市場帶來重大挑戰。開發針對這些疾病的疫苗通常需要廣泛的研究和開發，並且上市時間可能與解決疾病爆發的緊迫性不符。一些病原體，如流感病毒，表現出抗原變異性，這意味著它們可以隨著時間的推移而突變。這種變異性可能會降低現有疫苗的有效性，從而需要頻繁更新和重新配製。這給疫苗製造商帶來了技術和後勤方面的挑戰，以保持領先於不斷變化的病原體。有些疾病，特別是可以在動物和人類之間傳播的人畜共通傳染病，可能在野生動物中擁有宿主。由於野生動物接種疫苗很困難，透過疫苗接種來控制這些疾病可能具有挑戰性。

主要市場趨勢

日益關注預防性醫療保健：

全球獸用疫苗市場的一個突出趨勢是越來越重視動物的預防保健。寵物主人和牲畜生產者正在認知到疫苗接種作為保護動物免受傳染病侵害的主動措施的重要性。預防性醫療保健不僅可以改善動物的整體健康狀況，還可以減輕與治療患病動物相關的經濟負擔。

這一趨勢在伴侶動物領域尤其明顯，寵物主人更願意投資常規疫苗接種，以確保寵物的健康和長壽。在畜牧業中，預防性疫苗接種正成為維持牛群健康和生產力的標準做法。

疫苗技術的進步：

疫苗技術的進步正在推動獸用疫苗市場的創新。這些進步涵蓋了疫苗開發、生產和管理的各個方面：研究人員正在探索新的疫苗平台，例如 DNA 疫苗、重組疫苗和病毒樣顆粒疫苗。這些平台提供了更高的安全性、有效性和生產簡易性。改進的佐劑和輸送系統正在提高疫苗的有效性並減少加強注射的需要。這些創新使寵物主人和牲畜生產者更方便地接種疫苗。基因組學和抗原發現的進步使得能夠開發出針對特定病原體提供更好保護的標靶和客製化疫苗。這一趨勢對於應對新出現和不斷演變的疾病尤其重要。

全球化與市場擴張：

在全球化和動物產品貿易增加的推動下，全球獸用疫苗市場正經歷顯著擴張。幾個相關趨勢促成了這種成長：

亞洲、拉丁美洲和非洲的新興市場對獸用疫苗的需求正在增加。隨著這些地區的經濟發展和城市化，對動物性蛋白質和寵物的需求不斷增加，從而推動了對疫苗的需求。動物和動物產品的國際貿易需要遵守國際健康和安全標準。這反過來又增加了對疫苗的需求，以確保運輸途中動物的健康和安全。疫苗製造商正在建立合作和夥伴關係，以擴大其全球影響力並進入新市場。這包括合資企業、許可協議和分銷合作夥伴關係。

細分市場洞察

疫苗類型見解

根據疫苗類型類別，牲畜疫苗細分市場將在 2022 年成為全球獸用疫苗市場的主導者。牲畜疫苗細分市場在全球獸用疫苗市場中的主導地位可歸因於與類型相關的多個因素畜牧業中使用的疫苗。牲畜疫苗專門用於滿足各種農場動物（包括牛、豬、家禽、綿羊和山羊）的健康和疾病預防需求。

牲畜疫苗涵蓋針對不同牲畜品種和特定疾病的多種疫苗類型。這種多樣性包括針對口蹄疫、牛呼吸道疾病、禽流感、豬圓環病毒相關疾病等疾病的疫苗。

畜牧業非常重視預防性醫療保健，以維持牛群健康和生產力。疫苗接種是這種方法的基石。牲畜疫苗的配製是為了保護動物免受可能因產量減少、死亡率增加和貿易限制而造成重大經濟損失的疾病。全球牲畜數量龐大，飼養了數十億頭動物來生產肉類、牛奶和其他產品。例如，全球有超過 15 億頭牛和近 250 億隻雞。如此龐大的人口對疫苗產生了巨大的需求，以保護這些動物免受傳染病的侵害。畜牧業是全球農業的重要組成部分，為許多國家的糧食安全和經濟穩定做出了貢獻。因此，牲畜疾病爆發的經濟影響可能是巨大的，從而推動了疫苗接種的需求。牲畜很容易感染一系列傳染病，其中一些具有高度傳染性，可以在牛群或羊群中迅速傳播。控制和預防這些疾病通常需要採取多方面的方法，其中疫苗接種是關鍵組成部分。一些牲畜疾病可能具有人畜共患病的可能性，這意味著它們可以從動物傳播給人類。透過疫苗接種來預防這些疾病不僅對動物健康至關重要，而且對公共衛生也至關重要。預計這些因素將推動該領域的成長。

技術洞察

減毒活疫苗領域預計將在預測期內快速成長。減毒活疫苗是一類含有其針對的病原體的弱化或修飾形式的疫苗。與其他類型的疫苗相比，減毒活疫苗通常能提供更強、更持久的免疫反應。這是因為它們非常模仿自然感染，刺激體液（抗體）和細胞免疫。

在許多情況下，減毒活疫苗需要較少的劑量即可獲得持久的免疫力。這在獸醫環境中特別有利，因為施用多次劑量可能具有挑戰性，特別是對於農場動物。減毒活疫苗在根除或控制多種毀滅性動物疾病方面發揮了至關重要的作用。例如，使用減毒活疫苗有助於控制牛瘟和豬偽狂犬病等疾病。一旦疾病爆發，可以迅速部署減毒活疫苗來控制疾病的傳播並保護脆弱的動物族群。減毒活疫苗通常可以針對病原體的多種菌株或變種提供交叉保護。這在處理表現出抗原變異的病原體時特別有價值。減毒活疫苗可用於預防多種病毒和細菌性疾病，使其成為獸醫和牲畜生產者的多功能工具。這些因素共同促進了該細分市場的成長。

區域洞察

2022年，北美成為全球獸用疫苗市場的主導者，以價值計算，佔據最大的市場佔有率。美國擁有大量寵物，包括狗、貓和馬，導致對伴侶動物疫苗的大量需求。北美畜牧業發達，牛肉和乳製品產量高。這導致對牲畜疫苗的大量需求，以維持畜群健康和生產力。該地區擁有領先的獸醫研究機構和疫苗製造商，推動了新疫苗技術的創新和開發。

亞太市場可望成為成長最快的市場，在預測期內為獸用疫苗廠商提供利潤豐厚的成長機會。因素隨著亞太地區國家快速都市化和經濟發展，對動物性蛋白質的需求不斷增加，導致畜牧業不斷發展。中國和印度等國家的寵物數量迅速增加，寵物主人對寵物醫療保健（包括疫苗接種）的投資意識和意願增強。一些亞太國家面臨畜禽地方病的持續挑戰。政府和農民擴大利用疫苗作為疾病控制手段，以確保糧食安全。該地區對獸醫保健基礎設施的投資正在增加，包括疫苗接種計劃和新疫苗的研發。一些亞太地區政府正在實施促進動物性產品生產的政策，其中包括推廣疫苗接種以改善牲畜健康。

目錄

第 1 章：產品概述

• 市場定義
• 市場範圍
  • 涵蓋的市場
  • 研究年份
  • 主要市場區隔

第 2 章：研究方法

• 研究目的
• 基線方法
• 主要產業夥伴
• 主要協會和二手資料來源
• 預測方法
• 數據三角測量與驗證
• 假設和限制

第 3 章：執行摘要

• 市場概況
• 主要市場細分概述
• 主要市場參與者概述
• 重點地區/國家概況

第 4 章：市場促進因素、挑戰、趨勢概述

第 5 章：客戶之聲

第 6 章：全球獸用疫苗市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依疫苗類型（牲畜疫苗、伴侶動物疫苗）
  • 依技術分類（減毒活疫苗、不活化疫苗、類毒素疫苗、重組疫苗、其他）
  • 按地區
  • 按公司分類 (2022)
• 市場地圖

第 7 章：北美獸用疫苗市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按疫苗類型
  • 依技術
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第 8 章：歐洲獸用疫苗市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按疫苗類型
  • 依技術
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 9 章：亞太地區獸用疫苗市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按疫苗類型
  • 依技術
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 10 章：南美洲獸用疫苗市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按疫苗類型
  • 依技術
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 11 章：中東和非洲獸用疫苗市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按疫苗類型
  • 依技術
• MEA：國家分析
  • 南非獸用疫苗
  • 沙烏地阿拉伯獸用疫苗
  • 阿拉伯聯合大公國獸用疫苗

第 12 章：市場動態

• 促進因素與挑戰

第 13 章：市場趨勢與發展

• 最近的發展
• 產品發布
• 併購

第 14 章：全球獸用疫苗市場：SWOT 分析

第15章：競爭格局

• 商業概覽
• 技術產品
• 最近的發展
• 主要人員
• SWOT分析
  • Zoetis Inc.
  • Merck & Co. Inc.
  • Virbac
  • Hester Biosciences Limited
  • Elanco Animal Health
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Phibro Animal Health Corporation
  • HIPRA

第 16 章：策略建議

第 17 章：關於我們與免責聲明

In 2022, the Global Veterinary Vaccines Market reached a valuation of USD 8.44 billion, and it is expected to demonstrate impressive growth in the forecasted period, achieving a Compound Annual Growth Rate (CAGR) of 7.28% through 2028. This market is an essential component within the broader veterinary healthcare industry, encompassing the research, production, and distribution of vaccines designed to prevent and manage diseases in animals, including both companion animals (pets) and livestock. Veterinary vaccines play a pivotal role in preserving animal health, ensuring food security, and mitigating the spread of zoonotic diseases, which can be transmitted between animals and humans.

The population of companion animals, including dogs, cats, and horses, is continually increasing on a global scale. Pet owners are increasingly willing to invest in healthcare for their animals, including vaccinations, to safeguard their well-being and extend their lifespan.

Key Market Drivers

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 8.44 Billion
Market Size 2028	USD 12.88 Billion
CAGR 2023-2028	7.28%
Fastest Growing Segment	Live Atteneuated Vaccines
Largest Market	North America

Rising Incidence of Animal Diseases

The global veterinary vaccine market is significantly influenced by the increasing incidence of infectious diseases among animals. These diseases can affect various species, including livestock (cattle, poultry, swine) and companion animals (dogs, cats). Examples of such diseases include foot-and-mouth disease, avian influenza, bovine respiratory disease, and canine parvovirus. Animal diseases can have severe economic consequences. Outbreaks can lead to reduced livestock productivity, increased mortality rates, and trade restrictions. For farmers and livestock producers, this translates into substantial financial losses. To mitigate these impacts, vaccines are developed and administered to prevent the occurrence and spread of these diseases. The concept of One Health emphasizes the interconnectedness of human, animal, and environmental health. Preventing animal diseases is not only essential for the well-being of animals but also for public health. Diseases that can jump from animals to humans (zoonoses) highlight the importance of veterinary vaccines in safeguarding both animal and human populations.

Growing Awareness of Animal Welfare

There is a notable shift in public attitudes toward animal welfare, driven by increased awareness and concern for the well-being of animals. Pet owners are more willing to invest in healthcare for their pets, including vaccinations, to ensure their health and longevity. In the livestock industry, there is a growing recognition that healthy and well-cared-for animals lead to higher productivity and food safety. Consumers are increasingly demanding ethically and sustainably sourced animal products, which incentivizes livestock producers to prioritize animal health and welfare. Regulatory bodies and animal welfare organizations have introduced guidelines and certification programs that encourage the humane treatment of animals. These guidelines often include recommendations for disease prevention through vaccination.

Technological Advancements in Vaccine Development

Advances in biotechnology and genomics have revolutionized vaccine development. Researchers can now identify antigens more precisely and design vaccines tailored to specific pathogens. This has led to the development of subunit vaccines and recombinant vaccines with improved safety profiles. Technological innovations have also improved vaccine delivery methods. Traditional injectable vaccines are being supplemented with alternatives such as oral vaccines and intranasal vaccines, which can be administered more easily and with reduced stress for animals. Modern vaccine development techniques enable the creation of vaccines that are both highly efficacious and safe. This instills confidence in veterinarians, pet owners, and livestock producers, encouraging greater vaccine adoption.

Government Initiatives and Regulations:

Many governments around the world have implemented mandatory vaccination programs for specific diseases in animals. For example, bovine brucellosis vaccination is required in cattle in some regions to prevent the disease's spread. Vaccination of livestock is often tied to food safety and international trade regulations. Governments may require certain vaccinations to ensure the safety of animal-derived products for human consumption and to facilitate international trade. Governments and public health agencies often fund research and development efforts related to animal vaccines. This financial support can lead to the discovery and development of new and improved vaccines for various animal species.

Key Market Challenges

Regulatory Hurdles and Approval Processes

Complex Regulatory Landscape: Developing and marketing veterinary vaccines involves navigating a complex regulatory landscape. Different countries and regions have their own regulatory agencies and requirements for vaccine approval. Complying with these regulations can be time-consuming and costly for vaccine manufacturers.

Stringent Safety and Efficacy Standards: Regulatory agencies impose stringent safety and efficacy standards on veterinary vaccines to ensure the well-being of animals and prevent potential risks to human health. Meeting these standards often requires extensive preclinical and clinical testing, which can be expensive and time intensive.

Vaccine Registration Delays: Delays in the registration and approval of veterinary vaccines can significantly slow down market growth. Manufacturers must invest in research, development, and clinical trials, and any delays in the approval process can hinder their ability to bring vaccines to market in a timely manner.

Market Fragmentation and Competitive Challenges

The global veterinary vaccine market is fragmented, with many manufacturers, including both multinational pharmaceutical companies and smaller, specialized firms. This fragmentation can lead to intense competition and pricing pressures. Customers, such as farmers and pet owners, are often price-sensitive when it comes to veterinary vaccines. This can make it challenging for vaccine manufacturers to maintain profitability, particularly when competing with lower-cost alternatives. Expanding into emerging markets can be difficult due to variations in regulatory requirements, distribution channels, and local preferences. Manufacturers must adapt their strategies to suit each market, which can be resource intensive.

Emerging Diseases and Antigenic Variability

The emergence of new and unpredictable animal diseases can pose significant challenges to the veterinary vaccine market. Developing vaccines for these diseases often requires extensive research and development, and the timeline to market may not align with the urgency of addressing disease outbreaks. Some pathogens, like influenza viruses, exhibit antigenic variability, meaning they can mutate over time. This variability can render existing vaccines less effective, necessitating frequent updates and reformulations. This poses technical and logistical challenges for vaccine manufacturers to stay ahead of evolving pathogens. Some diseases, particularly zoonotic diseases that can be transmitted between animals and humans, may have reservoir hosts in wildlife. Controlling these diseases through vaccination can be challenging due to the difficulty of vaccinating wild animals.

Key Market Trends

Increasing Focus on Preventive Healthcare:

One prominent trend in the global veterinary vaccine market is the increasing emphasis on preventive healthcare for animals. Pet owners and livestock producers are recognizing the importance of vaccination as a proactive measure to protect animals from infectious diseases. Preventive healthcare not only improves the overall well-being of animals but also reduces the economic burden associated with treating sick animals.

This trend is particularly evident in the companion animal sector, where pet owners are more willing to invest in routine vaccinations to ensure the health and longevity of their pets. In the livestock industry, preventive vaccination is becoming standard practice to maintain herd health and productivity.

Advancements in Vaccine Technology:

Advances in vaccine technology are driving innovation in the veterinary vaccine market. These advancements encompass various aspects of vaccine development, production, and administration: Researchers are exploring new vaccine platforms, such as DNA vaccines, recombinant vaccines, and virus-like particle vaccines. These platforms offer improved safety, efficacy, and ease of production. Improved adjuvants and delivery systems are enhancing vaccine effectiveness and reducing the need for booster shots. These innovations are making vaccines more convenient for both pet owners and livestock producers. Advances in genomics and antigen discovery are enabling the development of targeted and customized vaccines that provide better protection against specific pathogens. This trend is particularly relevant for addressing emerging and evolving diseases.

Globalization and Market Expansion:

The global veterinary vaccine market is experiencing significant expansion, driven by globalization and increased trade in animal products. Several related trends contribute to this growth:

Emerging markets in Asia, Latin America, and Africa are witnessing a rise in demand for veterinary vaccines. As these regions undergo economic development and urbanization, the demand for animal protein and pet ownership is increasing, driving the need for vaccines. The international trade of animals and animal products necessitates compliance with international health and safety standards. This, in turn, boosts the demand for vaccines to ensure the health and safety of animals in transit. Vaccine manufacturers are forming collaborations and partnerships to expand their global presence and access new markets. This includes joint ventures, licensing agreements, and distribution partnerships.

Segmental Insights

Vaccine Type Insights

Based on the category of Vaccine Type, the livestock vaccine segment emerged as the dominant player in the global market for Veterinary Vaccines in 2022. The dominance of the livestock vaccine segment in the global veterinary vaccine market can be attributed to several factors related to the types of vaccines used in the livestock industry. Livestock vaccines are specifically designed to address the health and disease prevention needs of various farm animals, including cattle, swine, poultry, sheep, and goats.

The Livestock vaccines encompass a wide range of vaccine types tailored to different livestock species and specific diseases. This diversity includes vaccines for diseases like foot-and-mouth disease, bovine respiratory disease, avian influenza, porcine circovirus-associated disease, and many others.

The livestock industry places a strong emphasis on preventive healthcare to maintain herd health and productivity. Vaccination is a cornerstone of this approach. Livestock vaccines are formulated to protect animals from diseases that can cause substantial economic losses through reduced production, increased mortality, and trade restrictions. The global livestock population is immense, with billions of animals raised for meat, milk, and other products. For example, there are over 1.5 billion cattle and nearly 25 billion chickens globally. Such large populations create a significant demand for vaccines to protect these animals from infectious diseases. Livestock farming is a vital component of the global agriculture industry, contributing to food security and economic stability in many countries. Consequently, the economic impact of disease outbreaks in livestock can be substantial, driving the need for vaccination. Livestock can be vulnerable to a range of infectious diseases, some of which are highly contagious and can spread rapidly within herds or flocks. Controlling and preventing these diseases often requires a multifaceted approach, with vaccination being a critical component. Some livestock diseases can have zoonotic potential, meaning they can be transmitted from animals to humans. Preventing these diseases through vaccination is not only essential for animal health but also for public health. These factors are expected to drive the growth of this segment.

Technology Insights

The live attenuated vaccines segment is projected to experience rapid growth during the forecast period. Live attenuated vaccines are a category of vaccines that contain weakened or modified forms of the pathogen they target. Live attenuated vaccines often provide a stronger and more sustained immune response compared to other types of vaccines. This is because they closely mimic natural infections, stimulating both humoral (antibody) and cellular immunity.

In many cases, live attenuated vaccines require fewer doses to confer long-lasting immunity. This is particularly advantageous in veterinary settings where administering multiple doses can be challenging, especially for farm animals. Live attenuated vaccines have played a crucial role in eradicating or controlling several devastating animal diseases. For example, the use of live attenuated vaccines has been instrumental in controlling diseases like rinderpest in cattle and pseudorabies in pigs. In the event of disease outbreaks, live attenuated vaccines can be rapidly deployed to control the spread of the disease and protect vulnerable populations of animals. Live attenuated vaccines often provide cross-protection against multiple strains or variants of a pathogen. This is particularly valuable when dealing with pathogens that exhibit antigenic variation. Live attenuated vaccines can be used to protect against a wide range of viral and bacterial diseases, making them versatile tools for veterinarians and livestock producers. These factors collectively contribute to the growth of this segment.

Regional Insights

North America emerged as the dominant player in the global Veterinary Vaccines market in 2022, holding the largest market share in terms of value. The United States has a significant population of pets, including dogs, cats, and horses, leading to a substantial demand for companion animal vaccines. North America boasts a well-developed livestock industry, with high-quality beef and dairy production. This has led to a substantial need for livestock vaccines to maintain herd health and productivity. The region is home to leading veterinary research institutions and vaccine manufacturers, driving innovation and the development of new vaccine technologies.

The Asia-Pacific market is poised to be the fastest-growing market, offering lucrative growth opportunities for Veterinary Vaccines players during the forecast period. Factors As APAC countries undergo rapid urbanization and economic development, there is an increasing demand for animal protein, leading to a growing livestock industry. Countries like China and India have rapidly expanding pet populations, with pet owners showing greater awareness of and willingness to invest in pet healthcare, including vaccinations. Some APAC countries face ongoing challenges with endemic diseases in livestock and poultry. Governments and farmers are increasingly turning to vaccines as a means of disease control to ensure food security. The region is witnessing increased investment in veterinary healthcare infrastructure, including vaccination programs and research and development of new vaccines. Some APAC governments are implementing policies to boost the production of animal-derived products, which includes promoting vaccination to improve livestock health.

Key Market Players

• Zoetis Inc.

• Merck & Co. Inc.

• Virbac SA

• Hester Biosciences Limited

• Elanco Animal Health

• Boehringer Ingelheim International GmbH

• Ceva Sante Animale

• Phibro Animal Health Corporation

• HIPRA

Report Scope:

In this report, the Global Veterinary Vaccines Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Vaccines Market, By Vaccine Type:

• Livestock Vaccine
• Companion Animal Vaccine

Veterinary Vaccines Market, By Technology:

• Live Attenuated Vaccines
• Inactivated Vaccines
• Toxoid Vaccines
• Recombinant Vaccines
• Other

Veterinary Vaccines Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Vaccines Market.

Available Customizations:

• Global Veterinary Vaccines market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries

4. Overview of Market Drivers, Challenges, Trends

5. Voice of Customer

6. Global Veterinary Vaccines Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Vaccine Type (Livestock Vaccine, Companion Animal Vaccine)
  • 6.2.2. By Technology (Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Other)
  • 6.2.3. By Region
  • 6.2.4. By Company (2022)
• 6.3. Market Map

7. North America Veterinary Vaccines Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Vaccine Type
  • 7.2.2. By Technology
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Veterinary Vaccines Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Vaccine Type
      • 7.3.1.2.2. By Technology
  • 7.3.2. Canada Veterinary Vaccines Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Vaccine Type
      • 7.3.2.2.2. By Technology
  • 7.3.3. Mexico Veterinary Vaccines Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Vaccine Type
      • 7.3.3.2.2. By Technology

8. Europe Veterinary Vaccines Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Vaccine Type
  • 8.2.2. By Technology
• 8.3. Europe: Country Analysis
  • 8.3.1. Germany Veterinary Vaccines Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Vaccine Type
      • 8.3.1.2.2. By Technology
  • 8.3.2. United Kingdom Veterinary Vaccines Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Vaccine Type
      • 8.3.2.2.2. By Technology
  • 8.3.3. Italy Veterinary Vaccines Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecasty
      • 8.3.3.2.1. By Vaccine Type
      • 8.3.3.2.2. By Technology
  • 8.3.4. France Veterinary Vaccines Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Vaccine Type
      • 8.3.4.2.2. By Technology
  • 8.3.5. Spain Veterinary Vaccines Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Vaccine Type
      • 8.3.5.2.2. By Technology

9. Asia-Pacific Veterinary Vaccines Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Vaccine Type
  • 9.2.2. By Technology
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Veterinary Vaccines Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Vaccine Type
      • 9.3.1.2.2. By Technology
  • 9.3.2. India Veterinary Vaccines Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Vaccine Type
      • 9.3.2.2.2. By Technology
  • 9.3.3. Japan Veterinary Vaccines Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Vaccine Type
      • 9.3.3.2.2. By Technology
  • 9.3.4. South Korea Veterinary Vaccines Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Vaccine Type
      • 9.3.4.2.2. By Technology
  • 9.3.5. Australia Veterinary Vaccines Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Vaccine Type
      • 9.3.5.2.2. By Technology

10. South America Veterinary Vaccines Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Vaccine Type
  • 10.2.2. By Technology
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Veterinary Vaccines Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Vaccine Type
      • 10.3.1.2.2. By Technology
  • 10.3.2. Argentina Veterinary Vaccines Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Vaccine Type
      • 10.3.2.2.2. By Technology
  • 10.3.3. Colombia Veterinary Vaccines Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Vaccine Type
      • 10.3.3.2.2. By Technology

11. Middle East and Africa Veterinary Vaccines Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Vaccine Type
  • 11.2.2. By Technology
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Veterinary Vaccines Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Vaccine Type
      • 11.3.1.2.2. By Technology
  • 11.3.2. Saudi Arabia Veterinary Vaccines Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Vaccine Type
      • 11.3.2.2.2. By Technology
  • 11.3.3. UAE Veterinary Vaccines Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Vaccine Type
      • 11.3.3.2.2. By Technology

12. Market Dynamics

• 12.1. Drivers & Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Product Launches
• 13.3. Mergers & Acquisitions

14. Global Veterinary Vaccines Market: SWOT Analysis

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Technology Offerings
• 15.3. Recent Developments
• 15.4. Key Personnel
• 15.5. SWOT Analysis
  • 15.5.1. Zoetis Inc.
  • 15.5.2. Merck & Co. Inc.
  • 15.5.3. Virbac
  • 15.5.4. Hester Biosciences Limited
  • 15.5.5. Elanco Animal Health
  • 15.5.6. Boehringer Ingelheim International GmbH
  • 15.5.7. Ceva Sante Animale
  • 15.5.8. Phibro Animal Health Corporation
  • 15.5.9. HIPRA

16. Strategic Recommendations

17. About Us & Disclaimer